Lupus Research Program Idea Award

Award Info:

All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.


The LRP Idea Award supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. This award mechanism supports studies that have the potential to reveal entirely new avenues for investigation. The LRP mission is to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life of patients, including Service members, Veterans, and beneficiaries. The LRP vision is to cure lupus through partnership of scientists, clinicians, and consumers.

To be considered for funding, applications for the FY20 LRP Idea Award are required to address at least one of the following FY20 LRP Focus Areas:
• Understanding how lupus disease heterogeneity impacts risk of disease, disease presentation, clinical course, and outcomes; using a diverse range of research disciplines including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment studies, health economics, socioeconomic studies, environmental studies, and epidemiological studies.
• Understanding lupus disease heterogeneity including, but not limited to, strategies and technologies to subtype patients and understanding lupus disease mechanisms.
• Improving quality of life for individuals living with lupus including, but not limited to, access to healthcare resources, outcomes research, symptom control, comparative effectiveness research, and issues and challenges that when addressed make day-to-day living with lupus easier and life more fulfilling.
• Understanding how the underlying genetic components and gene-environment interactions of lupus relate to clinical disease characteristics using functional genomic studies.
• Determining the pathobiology of lupus disease in target human tissues including, but not limited to, imaging studies, genomics of lupus in particular tissues, and metabolomics.